[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544069":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":48,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":20,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":71,"whyStopped":20,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Nova Scotia Health Authority","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participant Group","EXPERIMENTAL","Participants who meet eligibility criteria and provide informed consent.",[13],"Device: Neuromodulation programming",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Neuromodulation programming","Participants will be brought in for their standard follow-up appointments at 4-weeks, 4-months, and 1-year post-surgery. In addition to the routine care, physiological data will be extracted from the implanted device and analyzed. The physiological data will be considered along with the standard epilepsy diary to assess epileptic burden and inform device programming.\n\nQuality of life will be measured with a series of standard questionnaires pre-surgery and at the 1-year follow-up.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Lutz Weise, MD, PhD","Dalhousie University","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","902-472-6850","lutz.weise@nshealth.ca",[32],{"facility":33,"status":20,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Queen Elizabeth Health Science Centre","Halifax","Nova Scotia","B3H 3A7","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-63.57688,44.64269,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":20,"phoneExt":20,"email":20},"Lutz Weise",{"type":25,"investigatorFullName":47,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Principal Investigator","100544069","enhancing-epilepsy-management-with-precision-deep-brain-stimulation-100544069",false,"NCT06364085","Enhancing Epilepsy Management With Precision Deep Brain Stimulation","EPI-BOOST: Enhancing Epilepsy Management With Precision Deep Brain Stimulation","EPI-BOOST","Inclusion Criteria:\n\n* Patients qualifying for deep brain stimulation on the basis of drug-resistant epilepsy\n* Informed consent\n\nExclusion Criteria:\n\n* Lack of consent\n* Electrical or other devices that preclude the performance of an MRI for pre-operative imaging","ALL",{"count":60,"type":61},40,"ESTIMATED","INTERVENTIONAL",[64],"NA","The goal of this study is to evaluate the effectiveness of objective neural response feedback on deep brain stimulation (DBS) programming for drug-resistant epilepsy in a prospective observational cohort study.",[67],"Epilepsy, Drug Resistant",[69,70],"Deep brain stimulation","DBS Programming","NOT_YET_RECRUITING","2024-04-08",{"date":74,"type":75},"2024-04-15","ACTUAL",{"date":77,"type":61},"2024-06",{"date":79,"type":61},"2026-06",{"name":5,"class":6},1]